AbbVie
ABBV
2,003 hedge funds and large institutions have $80.2B invested in AbbVie in 2019 Q3 according to their latest regulatory filings, with 124 funds opening new positions, 858 increasing their positions, 798 reducing their positions, and 123 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 52 → 73 (+21)
5% more capital invested
Capital invested by funds: $76.4B → $80.2B (+$3.84B)
1.97% more ownership
Funds ownership: 69.7% → 71.67% (+2%)
8% more repeat investments, than reductions
Existing positions increased: 858 | Existing positions reduced: 798
1% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 123
1% less funds holding
Funds holding: 2,020 → 2,003 (-17)
7% less call options, than puts
Call options by funds: $1.63B | Put options by funds: $1.75B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$724M |
| 3 |
JP Morgan Chase
New York
|
+$629M |
| 4 |
BlackRock
New York
|
+$229M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$200M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$652M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$457M |
| 3 |
Janus Henderson Group
London,
|
-$350M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$178M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$162M |
ABBV Hedge Fund Activity: Q3 2019 in Review
2,003 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2019, worth a combined $80.2B — up 5% from $76.4B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new ABBV positions and 123 closed out — a net gain of 1 holder — while 858 added to existing stakes and 798 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $1B. The largest seller was Capital Research Global Investors, cutting an estimated $652M.
- 2,003 institutional investors held AbbVie (ABBV) as of Q3 2019, down from 2,020 in Q2 2019.
- Funds reported $80.2B of AbbVie stock for Q3 2019, up 5% quarter-over-quarter.
- 124 funds opened new AbbVie positions in Q3 2019 and 123 closed out, a net change of +1 holder.
- The largest AbbVie buyer in Q3 2019 was T. Rowe Price Associates, an estimated $1B added.
- The largest AbbVie seller in Q3 2019 was Capital Research Global Investors, an estimated $652M sold.
Based on aggregated 13F filings for Q3 2019.